CA
NZ
UK
AU
IND
US
…
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Embecta Corp manufactures and supplies insulin delivery systems, infusion sets and related disposable components for people with diabetes, serving both direct customers and device manufacturers. Long-term growth drivers include rising global diabetes prevalence, consumable repeat revenue, product development and geographic expansion, which may benefit scale and margins and make the company attractive for exposure to the diabetes device market.
The most important investment risks are regulatory and reimbursement changes, competitive pressure from larger medical-device companies and execution risk in scaling manufacturing and commercial adoption.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Income before tax | 136.30M | 44.20M | 105.70M | 256.60M | 495.00M |
| Net income | 95.40M | 78.30M | 70.40M | 223.60M | 415.00M |
| Selling general administrative | 318.00M | 356.10M | 341.30M | 294.80M | 240.00M |
| Selling and marketing expenses | 16.20M | 9.00M | - | - | 240.00M |
| Gross profit | 679.50M | 728.90M | 749.90M | 774.90M | 800.00M |
| Reconciled depreciation | 40.70M | 36.20M | 32.60M | 31.70M | 38.00M |
| Ebit | 243.60M | 156.50M | 215.20M | 309.60M | 492.00M |
| Ebitda | 294.70M | 199.00M | 247.80M | 393.40M | 530.00M |
| Depreciation and amortization | 51.10M | 42.50M | 32.60M | 83.80M | 38.00M |
| Non operating income net other | - | - | - | -6.80M | - |
| Operating income | 329.30M | 174.20M | 221.50M | 309.60M | 492.00M |
| Other operating expenses | 751.10M | 948.90M | 896.80M | 761.00M | 673.00M |
| Interest expense | 107.30M | 112.30M | 107.00M | 46.20M | 3.00M |
| Tax provision | 40.90M | -34.10M | 35.30M | 33.00M | 80.00M |
| Net interest income | -107.30M | -112.30M | -107.00M | -46.20M | - |
| Non recurring | - | - | - | 58.90M | - |
| Income tax expense | 40.90M | -34.10M | 35.30M | 33.00M | 80.00M |
| Total revenue | 1080.40M | 1123.10M | 1120.80M | 1129.50M | 1165.00M |
| Total operating expenses | 350.20M | 554.70M | 525.90M | 406.40M | 308.00M |
| Cost of revenue | 400.90M | 394.20M | 370.90M | 354.60M | 365.00M |
| Total other income expense net | -193.00M | -130.00M | -11.30M | -53.00M | 3.00M |
| Net income from continuing ops | 95.40M | 78.30M | 70.40M | 223.60M | 415.00M |
| Net income applicable to common shares | - | - | - | 223.60M | 415.00M |
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Total assets | 1090.90M | 1285.30M | 1214.40M | 1086.40M | 788.00M |
| Intangible assets | 7.00M | 8.10M | - | 8.90M | 18.00M |
| Other current assets | 78.40M | 74.00M | 111.40M | 306.00M | 23.00M |
| Total liab | 1742.10M | 2023.60M | 2036.10M | 1977.80M | 194.00M |
| Total stockholder equity | -650.60M | -738.30M | -821.70M | -891.40M | 594.00M |
| Deferred long term liab | - | - | - | 46.10M | - |
| Other current liab | 174.40M | 243.40M | 286.90M | 246.50M | 110.00M |
| Common stock | 0.60M | 0.60M | 0.60M | 0.60M | 865.00M |
| Capital stock | 0.00M | 0.60M | 0.60M | 0.60M | 865.00M |
| Retained earnings | -445.60M | -498.60M | -541.10M | -577.10M | - |
| Other liab | - | - | - | 41.80M | 27.00M |
| Good will | 15.40M | 15.60M | - | 15.70M | 16.00M |
| Other assets | - | - | - | 89.20M | 7.00M |
| Cash | 225.50M | 267.50M | 326.50M | 330.90M | - |
| Total current liabilities | 261.50M | 374.00M | 353.50M | 301.00M | 164.00M |
| Net debt | 1204.80M | 1340.90M | 1312.00M | 1312.90M | - |
| Short term debt | 12.90M | 12.90M | 13.10M | 13.10M | - |
| Short long term debt | 9.50M | 9.50M | 9.50M | 9.50M | - |
| Short long term debt total | 1430.30M | 1608.40M | 1638.50M | 1643.80M | - |
| Other stockholder equity | 80.00M | 52.50M | 27.90M | 10.00M | -271.00M |
| Property plant equipment | - | - | - | 307.90M | 455.00M |
| Total current assets | 631.40M | 761.00M | 749.10M | 664.70M | 292.00M |
| Net tangible assets | - | - | - | -883.40M | 560.00M |
| Net receivables | 148.90M | 248.00M | 159.10M | 133.10M | 151.00M |
| Long term debt | 1388.70M | 1565.30M | 1593.90M | 1598.10M | - |
| Inventory | 178.60M | 171.50M | 152.10M | 122.80M | 118.00M |
| Accounts payable | 74.20M | 91.00M | 53.50M | 41.40M | 54.00M |
| Accumulated other comprehensive income | -285.60M | -292.80M | -309.10M | -324.90M | -271.00M |
| Common stock total equity | - | - | - | 0.60M | - |
| Retained earnings total equity | - | - | - | -577.10M | - |
| Non currrent assets other | 368.40M | 210.20M | 140.40M | 95.50M | 11.00M |
| Non current assets total | 459.50M | 524.30M | 465.30M | 421.70M | 496.00M |
| Capital lease obligations | 32.10M | 33.60M | 35.10M | 36.20M | - |
| Long term debt total | - | - | - | 1598.10M | - |
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Investments | -9.30M | -15.80M | -26.50M | -24.00M | -39.00M |
| Change to liabilities | - | - | - | 83.60M | 30.00M |
| Total cashflows from investing activities | -9.30M | -15.80M | - | -24.00M | -39.00M |
| Net borrowings | -186.00M | -35.90M | - | 1411.90M | 1443.40M |
| Total cash from financing activities | -226.70M | -73.40M | -48.70M | -48.00M | -417.00M |
| Change to operating activities | - | - | - | -90.50M | -12.00M |
| Net income | 95.40M | 78.30M | 70.40M | 223.60M | 415.00M |
| Change in cash | -45.60M | -52.30M | -4.40M | 330.90M | -417.00M |
| Begin period cash flow | 274.20M | 326.50M | 330.90M | 0.00M | 0.00M |
| End period cash flow | 228.60M | 274.20M | 326.50M | 330.90M | 0.00M |
| Total cash from operating activities | 191.70M | 35.70M | 67.70M | 412.20M | 456.00M |
| Depreciation | 40.70M | 36.20M | 32.60M | 31.70M | 38.00M |
| Other cashflows from investing activities | - | - | - | -0.40M | - |
| Dividends paid | 35.00M | 34.50M | 34.40M | 8.60M | 8.60M |
| Change to inventory | -6.10M | -16.50M | -28.80M | -23.40M | -18.00M |
| Change to account receivables | 44.20M | -174.70M | 7.00M | 122.70M | -32.00M |
| Sale purchase of stock | -5.70M | -3.00M | - | - | - |
| Other cashflows from financing activities | -5.70M | -3.00M | -3.60M | -32.80M | -417.00M |
| Change to netincome | - | - | - | 51.10M | 35.00M |
| Capital expenditures | 9.30M | 15.80M | 26.50M | 24.00M | 39.00M |
| Change receivables | - | - | - | 122.70M | - |
| Cash flows other operating | - | - | - | -80.30M | - |
| Cash and cash equivalents changes | - | - | - | 340.20M | - |
| Change in working capital | -23.70M | -47.70M | -80.00M | 92.40M | -32.00M |
| Stock based compensation | 31.60M | 26.30M | 21.50M | 18.70M | 13.00M |
| Other non cash items | 30.10M | 13.20M | 8.90M | 72.30M | 24.00M |
| Free cash flow | 182.40M | 19.90M | 41.20M | 388.20M | 417.00M |
Sector: Healthcare Industry: Medical Instruments & Supplies
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| EMBC Embecta Corp |
-0.31 4.73% |
6.25 | 3.46 | - | 0.28 | 2.61 | 1.53 | 5.86 |
| ISRG Intuitive Surgical Inc |
-16.75 3.73% |
432.01 | 43.30 | 31.35 | 12.25 | 7.35 | 11.63 | 30.22 |
| ESLOF EssilorLuxottica Société anonyme |
1.51 0.74% |
205.00 | 44.84 | 27.62 | 4.07 | 2.49 | 3.71 | 16.04 |
| ESLOY Essilor International SA |
2.86 2.87% |
102.66 | 41.68 | 27.25 | 3.94 | 2.45 | 3.71 | 16.04 |
| BDX Becton Dickinson and Company |
-0.46 0.23% |
197.88 | 31.62 | 13.76 | 2.25 | 2.04 | 2.93 | 13.40 |
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
| Name | Title | Year Born |
|---|---|---|
| Mr. Devdatt Kurdikar | Pres, CEO & Director | 1969 |
| Mr. Jacob P. Elguicze | Sr. VP & CFO | 1973 |
| Mr. Jeffrey Z. Mann | Sr. VP, Gen. Counsel, Head of Corp. Devel. & Corp. Sec. | 1973 |
| Mr. Ajay Kumar | Sr. VP & Chief HR Officer | 1971 |
| Mr. Shaun Curtis | Sr. VP of Global Manufacturing & Supply Chain | 1970 |
| Mr. Brian R. Capone | VP, Chief Accounting Officer & Corp. Controller | 1975 |
| Ms. Colleen Riley | Sr. VP & Chief Technology Officer | 1965 |
| Ms. Ginny Blocki | Sr. VP of Global Marketing & Product Management | NA |
| Mr. Tom Blount | Sr. VP & Pres of North America | 1974 |
| Mr. Slobodan Radumilo | Sr. VP & Pres of International | 1971 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...